March 07, 2024
Maximon, Marcuard Heritage, and GenTwo have announced the launch of a new longevity-related investment opportunity. Their proposal allows professional investors to get access to Maximon's portfolio of longevity companies via an actively managed certificate (AMC). According to Maximon, there have been many requests to launch an AMC focused on longevity. Therefore, Marcuard Heritage, a top...
December 27, 2023
The Longevity Investor Network has experienced significant growth and success over the past year. Our mission to connect innovative companies in the longevity sector with forward-thinking investors has seen remarkable achievements, particularly in 2023. Investors On the investor side, we have now over 200 longevity investors that form part of our robust network. Our investor...
March 22, 2023
2021 marked one of the biggest years in longevity financing, with 2022 following closely behind, according to a report by Longevity.Technology. Over the past ten years, the industry has grown in financing from $500 million in 2013 to a peak of $6.2 billion (2021). Despite taking a dip in 2022, investment in longevity appears to...
November 02, 2022
With news of H.E. Justin Sun’s plans to invest $51K into the Longevity Prize, a fund seeking to stimulate innovative research proposals, it appears that there is a marked interest within the crypto and tech communities in longevity science. Sun’s donation comes after Vitalik Buterin’s contribution of $130K and Stefan George’s $6.5K to the...
October 25, 2022
Coinbase CEO, Brian Armstrong, has announced his intention to sell 2% of his Coinbase stock and invest the funds into innovative longevity research in a move that could see ~$54 million put towards the advancement of longevity science. Visit the VitaDAO website to learn how you can get involved. Armstrong’s decision echoes that of other...
July 21, 2022
Marking one of VitaDAO’s largest investments to date, the decentralized organization has allocated $1,000,000 in funding to Turn.Bio. This company, also known as Turn Biotechnologies, plans to undertake preclinical efficacy testing of mRNA therapeutics intended to induce self-healing of the skin and eyes. Through this purchase of an equity stake, VitaDAO is investing into the...